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INTRODUCTION
Protein kinase C epsilon (PKCε) is known to increase endothelial nitric oxide synthase (eNOS) 
activity by binding to a specific receptor for activated C kinase (RACK-1), facilitating its 
translocation from the cytosol to the cell membrane for phosphorylation of eNOS at serine-1177 
to augment activity [1,2]. Previous in vitro and in vivo animal studies have demonstrated that 
PKCε activation stimulates eNOS activity, increasing nitric oxide (NO) release; whereas a peptide 
inhibitor that disrupts PKCε interaction with RACK-1 results in decreased NO release [3,4,5,6,7]. 
However, the modulation of PKC-mediated eNOS activity (Figure 1) is not well known in human 
endothelial cells. Moreover, elucidating the role of PKCε in regulating eNOS activity would be 
essential in the clinical setting of ischemic heart disease.  Re-establishing blood flow after 
thrombus removal results in endothelial dysfunction that is characterized by limited NO 
bioavailability and excess generation of reactive oxygen species (ROS) by eNOS during reperfusion 
(Figure 2).
Therefore, we aim to demonstrate enhancement and attenuation of NO release in cultured 
HUVECs using cell-permeable, myristic-acid conjugated PKCε activator (Myr-PKCε+), Myr-
HDAPIGYD (MW = 1097 g/mol), and inhibitor (Myr-PKCε-), N-Myr-EAVSLKPT (MW = 1054 g/mol), 
in the absence and presence of acetylcholine (Ach). Ach is a well-established positive control to 
activate eNOS via calcium calmodulin (CAM) and promote NO release from vascular endothelial 
cells [7, 8]. Determining NO release using selective cell permeable PKCε activator (Myr-PKCε+) 
and inhibitor peptides (Myr-PKCε-) in cultured HUVECs under normoxic conditions would provide 
a foundation to test these peptides under hypoxic-reoxygenation conditions when eNOS would 
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Figure 2. Schematic representation of PKC regulation of eNOS and mitochondrial-derived 
superoxide (O2
-)  release in myocardial I/R, adapted from [5]. I/R insult activates PKC and 
opening of mitochondrial potassium ATP channels resulting in uncoupled eNOS activity by 
PKCε.
Measurement of NO release from cultured HUVECs: Single-donor HUVECs (Lonza, 
Walkersville, MD) at passages 3-4 were grown to confluence in 6-well (106 cells/well) plates. NO 
release was measured in real time using a calibrated NO electrode following the administration of 
10 μM Myr-PKCε+ or 10 μM Myr-PKCε- treatments in the absence or presence of 10 μM Ach 
stimulation of NO release. All treatments were prepared in endothelial growth media (EGM). Basal 
NO release was determined by measuring the difference between wells with and without cells. 
Statistical Analysis: All data in the figures are presented as means ± S.E.M. ANOVA analysis using 
Student-Neuman-Keuls was used to assess statistical difference in NO release between basal 
levels vs Myr-PKCε+ treated or Myr-PKCε- treated cultured HUVECs in the absence and presence 
of Ach stimulation (Ach or EGM); p<0.05 were considered statistically significant.
Figure 1. Mechanism of action of Myr-PKCε activator (Myr-HDAPIGYD) and Myr-PKCε
inhibitor (N-Myr-EAVSLKPT), adapted from [1]. When activated by diacylglycerol (DG), PKCε
binds to specific receptor for activated C kinase (RACK) domain which translocates PKCε to 
interact with substrates (e.g. eNOS) to produce a physiologic response (left panel). Myr-PKCε+ 
(in green)  prolongs the active confirmation of PKCε to facilitate increased interaction with 
RACK, resulting in increased physiological response. Myr-PKCε- (in red) inhibits PKCε or 
translocation by binding to its specific RACK to reduce physiologic response (right panel). 
We hypothesize that Myr-PKCε+ would increase NO release, whereas Myr-PKCε- would 
decrease NO release from cultured HUVECs in the absence and presence of  Ach.
Figure 3. Illustration of NO electrode calibration setup (left), calibration curve (top right) and 
HUVEC NO measurement in 6-well plates (bottom).  The NO electrode was calibrated based on 
the following reaction: 2KNO2 + 2KI + 2H2SO4 → 2NO + I + 2H2O +2K2SO4 (e.g. y = 0.9346x + 
3.4828; R² = 0.997) that corresponded to a 25 nM to 200 nM range (right).  Dose responses are 
indicated by red arrows. 
Figure 5. NO release (picomoles) in cultured HUVECs (106 cells/well) following Myr-PKCε+ 
(10 μM) and Myr-PKCε- (10 μM) treatments in the absence and presence of ACh
stimulation. EGM represents  negative control containing only endothelial growth media 
without Ach; *p<0.05 vs. Basal values; #p<0.05 vs. Myr-PKCε+ treatments.
These results suggest that in cultured HUVECs, Myr-PKCε+ presumably increases 
NO release via activation of eNOS, whereas Myr-PKCε- attenuates eNOS activity by 
inhibiting its phosphorylation; thus these peptides demonstrate comparable 
effects across species in regulating NO release. The understanding of the role of 
eNOS modulation is important for developing therapeutic interventions in the 
context of human organ-ischemia reperfusion injury, in which uncoupled eNOS 
produces ROS instead of NO.
Basal NO release (83±12 pmol) was determined by measuring the difference between wells 
with and without HUVECs (n=9, P<0.05). In the absence of Ach stimulation, Myr-PKCε+ 
treatments significantly enhanced NO release to 136±13 pmol (n=6, p<0.05) and Myr-PKCε-
attenuated total NO release to 16±27 pmol (n=7, p<0.05) compared to basal levels. 
As a positive control, 10 μM Ach significantly enhanced NO release to 153±11 pmol above 
basal levels (p<0.05, n=20). In the presence of Ach simulation, Myr-PKCε+ still significantly 
increased NO release above basal levels to 129±17 pmol (p<0.05, n=8) and Myr-PKCε-
decreased NO release to 34±12 pmol, (p<0.05, n=7) compared to basal levels, as shown in 
Figure 5. 
Figure 4. Illustration of real-time NO release measurements in cultured HUVECs using calibrated 
NO electrode (left). Representative tracings of NO released from cultured HUVECs was measured 
after administration of the 10 μM PKCε activator (top right) or 10 μM inhibitor (bottom right) in 
the absence and presence of Ach (10 μM). Basal NO release was  determined by measuring the 
difference between a well containing cells and one well containing only endothelial growth media 
(EGM) without cells.  Picoamp responses (red arrows) were converted to  picomoles/106 cells 
based on the calibration curve of the NO electrode.
Attenuated NO release in cultured HUVECs after the administration of PKC inhibitor (PKCε-)
Enhanced  NO release in cultured HUVECs after the administration of PKC activator (PKCε+)
